title: In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
abstract: Oritavancin is a lipoglycopeptide that has been approved for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs) caused by susceptible organisms. Oritavancin causes cell death by inhibiting cell wall synthesis as well as depolarising and permeabilising the cellular membrane of Gram-positive pathogens. The activities of oritavancin in comparison with vancomycin, daptomycin and linezolid were determined against a collection of over 11000 recent clinical Gram-positive isolates from patient infections (2011-2014), including skin and skin-structure infections. A total of 7253 Staphylococcus aureus, 839 coagulase-negative staphylococci (CoNS), 1464 enterococci and 1637 β-haemolytic streptococci (βHS) were collected from the USA and Europe. Minimum inhibitory concentrations (MICs) were determined using Clinical and Laboratory Standards Institute (CLSI) broth microdilution methods, and susceptibility was determined using CLSI and US Food and Drug Administration (FDA) (for oritavancin) breakpoint criteria. Equivalent in vitro activity (MIC50/90, 0.015-0.03/0.06 μg/mL) was observed for oritavancin against meticillin-resistant S. aureus (MRSA), meticillin-susceptible S. aureus (MSSA) and Enterococcus faecalis in both regions. Slightly higher oritavancin MICs were obtained against CoNS, Streptococcus agalactiae, Enterococcus faecium (MIC90, 0.12 μg/mL) and against other βHS (MIC90, 0.25 μg/mL). Oritavancin demonstrated comparatively lower MICs than daptomycin and vancomycin when tested against multidrug-resistant S. aureus, vancomycin-resistant enterococci and erythromycin-resistant βHS. Oritavancin exhibited potent in vitro activity against the most common pathogens associated with ABSSSIs in the USA and Europe.
authors.affiliation: International Health Management Associates, Inc., 2122 Palmer Drive, Schaumburg, IL 60173, USA. Electronic address: dbiedenbach@ihmainc.com.
authors.forename: Douglas J
authors.initials: DJ
authors.lastname: Biedenbach
authors.affiliation: The Medicines Company, Saint-Laurent, Quebec, Canada.
authors.forename: Francis F
authors.initials: FF
authors.lastname: Arhin
authors.affiliation: The Medicines Company, Saint-Laurent, Quebec, Canada.
authors.forename: Gregory
authors.initials: G
authors.lastname: Moeck
authors.affiliation: International Health Management Associates, Inc., 2122 Palmer Drive, Schaumburg, IL 60173, USA.
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Lynch
authors.affiliation: International Health Management Associates, Inc., 2122 Palmer Drive, Schaumburg, IL 60173, USA.
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Sahm
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017576:Daptomycin / Q000494:pharmacology*; D024901:Drug Resistance, Multiple, Bacterial; D016983:Enterococcus / Q000187:drug effects* / Q000302:isolation & purification; D005060:Europe; D006020:Glycopeptides / Q000494:pharmacology*; D006801:Humans; D000069349:Linezolid / Q000494:pharmacology*; D000077427:Lipoglycopeptides; D008826:Microbial Sensitivity Tests; D009656:North America; D017192:Skin Diseases, Bacterial / Q000188:drug therapy / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy; D013210:Staphylococcus / Q000187:drug effects* / Q000302:isolation & purification; D013290:Streptococcal Infections / Q000188:drug therapy; D013291:Streptococcus / Q000187:drug effects* / Q000302:isolation & purification; D014640:Vancomycin / Q000494:pharmacology* / Q000031:analogs & derivatives
chemical_list: D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D014640:Vancomycin; D000069349:Linezolid; D017576:Daptomycin; C100708:oritavancin
keywords: Lipoglycopeptide; Skin and soft-tissue infection; Surveillance